Glaukos beats earnings and revenue expectations in Q1, but stock falls due to margin decline.

From Zacks Investment Research: 2025-05-01 12:48:00

Glaukos Corporation reported a narrower-than-expected adjusted loss of 22 cents per share in the first quarter of 2025, an improvement from the year-ago quarter. Revenue reached $106.7 million, up 24.6% year over year. The company’s gross profit increased 25.9%, but operating expenses rose as well. Glaukos reiterated its 2025 revenue guidance and expects net sales between $475-$485 million. Despite positive results, shares of GKOS dropped 6.6% in after-market trading. The company is focusing on product innovation and pipeline development, with challenges from Medicare LCD restrictions impacting stent performance.

In the medical industry, Glaukos carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Fresenius Medical Care, Masimo, and AdaptHealth. Fresenius Medical has an estimated growth rate of 28.9% for 2025 and a Zacks Rank #2 (Buy). Masimo, with a Zacks Rank of 2, has an estimated growth rate of 20% for 2025. AdaptHealth, also with a Zacks Rank #2, has an estimated earnings growth rate of 16.7% for 2025. Each company has its own unique factors affecting performance and growth.



Read more at Zacks Investment Research: GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline – May 1, 2025